Davies Peter, Koppel Jeremy
Litwin-Zucker Center for Research on Alzheimer's Disease, Feinstein Institute for Medical Research, Manhasset, NY 11030, USA.
Dialogues Clin Neurosci. 2009;11(2):159-69. doi: 10.31887/DCNS.2009.11.2/pdavies.
Treatment for Alzheimer's disease is entering a new and exciting phase, with several new drugs beginning clinical trials. Many of these new therapies are based on our best current understanding of the pathogenesis of Alzheimer's disease, and are designed to try to either slow or halt the progression of the disease. There are several different theories underlying the current efforts, and these are briefly reviewed. Therapies directed against some aspect of beta-amyloid formation, against neurofibrillary tangle formation and against the inflammatory response are all considered, as are the problems associated with each area. It is as yet unclear which, if any, of these approaches will be successful, but the high level of activity in each of these three fields provides some hope that an effective treatment for Alzheimer's disease is on the horizon.
阿尔茨海默病的治疗正进入一个全新且令人振奋的阶段,有几种新药已开始临床试验。这些新疗法中的许多都是基于我们目前对阿尔茨海默病发病机制的最佳理解而设计的,旨在减缓或阻止疾病的进展。当前的研究工作有几种不同的理论基础,在此将简要回顾。针对β-淀粉样蛋白形成的某些方面、神经原纤维缠结形成以及炎症反应的疗法均在考虑范围内,同时也会探讨与每个领域相关的问题。目前尚不清楚这些方法中是否有任何一种会取得成功,但这三个领域各自的高度活跃态势让人们看到了希望,即有效的阿尔茨海默病治疗方法即将出现。